Original Article

Long-Term Efficiency of Twice-Daily Exenatide in Type 2 Diabetes Mellitus: A Real-Life Study

Volume 28 · Issue 2 Publish Date: March 4, 2024
Full Text PDF
DOI
Mehmet Çağrı Ünal
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Gülsüm Ceren Terzioğlu
Department of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Deniz Yıldız Kaya
Department of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Mehmet Emin Arayıcı
Department of Preventive Oncology, Institute of Health Sciences, Dokuz Eylül University, İzmir, Turkey
Fırat Bayraktar
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Abdurrahman Çömlekci
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Tevfik Demir
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Ünal, M. Çağrı, Terzioğlu, G. C., Yıldız Kaya, D., Arayıcı, M. E., Bayraktar, F., Çömlekci, A., & Demir, T. (2024). Long-Term Efficiency of Twice-Daily Exenatide in Type 2 Diabetes Mellitus: A Real-Life Study. Endocrinology Research and Practice, 28(2), 77–81. https://doi.org/10.5152/erp.2024.23395
Full Text Full Text PDF

Abstract

Objective: Exenatide (twice daily) has been used as a glucagon-like peptide-1 receptor agonist in patients with diabetes with inadequate glycemic control for over a decade. In this paper, we aimed to investigate the long-term glycemic control and change in body weight in patients treated with exenatide.

Methods: A total of 287 patients who were treated with exenatide twice daily between 2012 and 2022 were included in this retrospective study. The changes in glycated hemoglobin (HbA1c) levels and body weight were assessed over time after exenatide administration. The administered insulin dosage and metabolic parameters were documented. The baseline data were compared over a period of 3 months to 3 years.

Results: The study included 101 (36%) males and 186 (64%) females, with an average age of 56.4 ± 10.7 years. The baseline HbA1c level was 8.0 ± 1.8%, and the body mass index was 38.8 ± 5.9 kg/m2 . The HbA1c level had decreased by 1.29% from the baseline at 3 months (P < .001), which continued up to 3 years (−0.63%, P=.010). During the 3-year period, body weight continued to decrease significantly (−12.1, P < .001). Glucose levels were significantly reduced, but the lipid levels and glomerular filtration rate after exenatide treatment were similar. Notably, exenatide administration resulted in a decrease in insulin dosage for patients treated with insulin.

Conclusion: Exenatide therapy produced continued improvements in glycemic control and progressive weight loss for 3 years in patients with diabetes in a real-life setting.

Cite this article as: Ünal MÇ, Terzioğlu GC, Yıldız Kaya D, et al. Long-term efficiency of twice-daily exenatide in type 2 diabetes mellitus: A real-life study. Endocrinol Res Pract. 2024;28(2):77-81

Article Info
Published In
Journal Endocrinology Research and Practice
Volume / Issue Volume 28 · Issue 2
Pages 77-81
History
Published Online March 4, 2024
Copyright
Affiliations
Mehmet Çağrı Ünal
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Gülsüm Ceren Terzioğlu
Department of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Deniz Yıldız Kaya
Department of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Mehmet Emin Arayıcı
Department of Preventive Oncology, Institute of Health Sciences, Dokuz Eylül University, İzmir, Turkey
Fırat Bayraktar
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Abdurrahman Çömlekci
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Tevfik Demir
Department of Endocrinology and Metabolism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
Cite this Article
Ünal, M. Çağrı, Terzioğlu, G. C., Yıldız Kaya, D., Arayıcı, M. E., Bayraktar, F., Çömlekci, A., & Demir, T. (2024). Long-Term Efficiency of Twice-Daily Exenatide in Type 2 Diabetes Mellitus: A Real-Life Study. Endocrinology Research and Practice, 28(2), 77–81. https://doi.org/10.5152/erp.2024.23395
Outlines